Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
Regul Toxicol Pharmacol ; 74: 117-22, 2016 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-26619782

RESUMO

The aim of this study was to evaluate the embryo-fetal development toxicity of honokiol microemulsion. The drug was intravenously injected to pregnant SD rats at dose levels of 0, 200, 600 and 2000 µg/kg/day from day 6-15 of gestation. All the pregnant animals were observed for body weights and any abnormal changes and subjected to caesarean-section on gestation day (GD) 20; all fetuses obtained from caesarean-section were assessed by external inspection, visceral and skeletal examinations. No treatment-related external alterations as well as visceral and skeletal malformations were observed in honokiol microemulsion groups. There was no significant difference in the body weight gain of the pregnant rats, average number of corpora lutea, and the gravid uterus weight in the honokiol microemulsion groups compared with the vehicle control group. However, at a dose level of 2000 µg/kg/day, there was embryo-fetal developmental toxicity observed, including a decrease in the body length and tail length of fetuses. In conclusion, the no-observed-adverse-effect level (NOAEL) of honokiol microemulsion is 600 µg/kg/day, 75 times above the therapeutic dosage and it has embryo-fetal toxicity at a dose level of 2000 µg/kg/day, which is approximately 250 times above the therapeutic dosage.


Assuntos
Compostos de Bifenilo/toxicidade , Embrião de Mamíferos/efeitos dos fármacos , Feto/efeitos dos fármacos , Lignanas/toxicidade , Fármacos Neuroprotetores/toxicidade , Animais , Compostos de Bifenilo/administração & dosagem , Relação Dose-Resposta a Droga , Embrião de Mamíferos/patologia , Emulsões , Feminino , Feto/patologia , Idade Gestacional , Injeções Intravenosas , Lignanas/administração & dosagem , Exposição Materna , Fármacos Neuroprotetores/administração & dosagem , Nível de Efeito Adverso não Observado , Gravidez , Ratos Sprague-Dawley , Medição de Risco
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA